Baumgartner Timothy J, Haghighijoo Zahra, Goode Nana A, Dvorak Nolan M, Arman Parsa, Laezza Fernanda
Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Life (Basel). 2023 Jul 29;13(8):1655. doi: 10.3390/life13081655.
Alzheimer's disease (AD) is the most common cause of dementia and is classically characterized by two major histopathological abnormalities: extracellular plaques composed of amyloid beta (Aβ) and intracellular hyperphosphorylated tau. Due to the progressive nature of the disease, it is of the utmost importance to develop disease-modifying therapeutics that tackle AD pathology in its early stages. Attenuation of hippocampal hyperactivity, one of the earliest neuronal abnormalities observed in AD brains, has emerged as a promising strategy to ameliorate cognitive deficits and abate the spread of neurotoxic species. This aberrant hyperactivity has been attributed in part to the dysfunction of voltage-gated Na (Nav) channels, which are central mediators of neuronal excitability. Therefore, targeting Nav channels is a promising strategy for developing disease-modifying therapeutics that can correct aberrant neuronal phenotypes in early-stage AD. This review will explore the role of Nav channels in neuronal function, their connections to AD pathology, and their potential as therapeutic targets.
阿尔茨海默病(AD)是痴呆最常见的病因,其典型特征是两种主要的组织病理学异常:由β淀粉样蛋白(Aβ)组成的细胞外斑块和细胞内高度磷酸化的tau蛋白。由于该疾病的进行性本质,开发在疾病早期阶段解决AD病理学问题的疾病修饰疗法至关重要。海马体活动亢进是在AD大脑中观察到的最早的神经元异常之一,减轻海马体活动亢进已成为改善认知缺陷和减少神经毒性物质扩散的一种有前景的策略。这种异常的活动亢进部分归因于电压门控钠(Nav)通道功能障碍,而电压门控钠通道是神经元兴奋性的核心介质。因此,靶向Nav通道是开发疾病修饰疗法的一种有前景的策略,这种疗法可以纠正早期AD中的异常神经元表型。本综述将探讨Nav通道在神经元功能中的作用、它们与AD病理学的联系以及它们作为治疗靶点的潜力。